These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 38888113)
1. Proteomic analysis of plasma in healthy adults receiving recombinant vaccinia virus provides novel insights into HIV-1 neutralizing antibodies. Chen R; Fu Y; Li D; Wang S; Ruan Y; Ren L; Wang S; Shen X; Shi Y; Shao Y; Liu Y J Med Virol; 2024 Jun; 96(6):e29749. PubMed ID: 38888113 [TBL] [Abstract][Full Text] [Related]
2. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828 [TBL] [Abstract][Full Text] [Related]
3. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394 [TBL] [Abstract][Full Text] [Related]
4. Early Pro-Inflammatory Signal and T-Cell Activation Associate With Vaccine-Induced Anti-Vaccinia Protective Neutralizing Antibodies. Hou J; Wang S; Li D; Carpp LN; Zhang T; Liu Y; Jia M; Peng H; Liu C; Wu H; Huang Y; Shao Y Front Immunol; 2021; 12():737487. PubMed ID: 34707608 [TBL] [Abstract][Full Text] [Related]
5. Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults. Joachim A; Nilsson C; Aboud S; Bakari M; Lyamuya EF; Robb ML; Marovich MA; Earl P; Moss B; Ochsenbauer C; Wahren B; Mhalu F; Sandström E; Biberfeld G; Ferrari G; Polonis VR PLoS One; 2015; 10(4):e0118486. PubMed ID: 25874723 [TBL] [Abstract][Full Text] [Related]
6. [A novel immunization strategy to induce strong humoral responses against HIV-1 using combined DNA, recombinant vaccinia virus and protein vaccines]. Liu C; Wang SH; Ren L; Hao YL; Zhang QC; Liu Y Bing Du Xue Bao; 2014 Nov; 30(6):645-51. PubMed ID: 25868279 [TBL] [Abstract][Full Text] [Related]
7. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894 [TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. Hayton EJ; Rose A; Ibrahimsa U; Del Sorbo M; Capone S; Crook A; Black AP; Dorrell L; Hanke T PLoS One; 2014; 9(7):e101591. PubMed ID: 25007091 [TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515 [TBL] [Abstract][Full Text] [Related]
10. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282 [TBL] [Abstract][Full Text] [Related]
11. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626 [TBL] [Abstract][Full Text] [Related]
12. Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. Joachim A; Bauer A; Joseph S; Geldmacher C; Munseri PJ; Aboud S; Missanga M; Mann P; Wahren B; Ferrari G; Polonis VR; Robb ML; Weber J; Tatoud R; Maboko L; Hoelscher M; Lyamuya EF; Biberfeld G; Sandström E; Kroidl A; Bakari M; Nilsson C; McCormack S PLoS One; 2016; 11(5):e0155702. PubMed ID: 27192151 [TBL] [Abstract][Full Text] [Related]
13. Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. Phillips B; Fouda GG; Eudailey J; Pollara J; Curtis AD; Kunz E; Dennis M; Shen X; Bay C; Hudgens M; Pickup D; Alam SM; Ardeshir A; Kozlowski PA; Van Rompay KKA; Ferrari G; Moody MA; Permar S; De Paris K Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28814388 [TBL] [Abstract][Full Text] [Related]
14. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus. van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570 [TBL] [Abstract][Full Text] [Related]
15. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E; PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299 [TBL] [Abstract][Full Text] [Related]
16. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049 [TBL] [Abstract][Full Text] [Related]
17. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431 [TBL] [Abstract][Full Text] [Related]
19. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. Cho MW; Kim YB; Lee MK; Gupta KC; Ross W; Plishka R; Buckler-White A; Igarashi T; Theodore T; Byrum R; Kemp C; Montefiori DC; Martin MA J Virol; 2001 Mar; 75(5):2224-34. PubMed ID: 11160726 [TBL] [Abstract][Full Text] [Related]
20. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network. Montefiori DC; Graham BS; Kliks S; Wright PF J Clin Immunol; 1992 Nov; 12(6):429-39. PubMed ID: 1287035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]